8-K ·Filed May 28, 2026

SNGX

SOLIGENIX, INC.
BEARISH
Impact 5/10
Horizonweeks Processed4mo ago SEC0001104659-26-067649
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The ATM increase signals ongoing cash needs and likely continued dilution. With $3.4M already sold and a $13M market cap, the company is relying on equity financing to fund operations. Monitor upcoming quarterly filings for cash runway and any pipeline catalysts that could alter the dilution trajectory.

DirectionBearish
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d ⚠ clustered
SNGX ▼ -55.53% at T+60d
SHORT call ✓ call won +55.53% · α vs SPY +56.71% · entry $0.9100 → $0.4047
Entry anchored
May 28, 03:59 PM ET
via exchange tick
T+1d
-9.31%
call +9.31% · α +9.58%
$0.8253
settled 4mo ago
T+5d
-47.25%
call +47.25% · α +46.96%
$0.4800
settled 4mo ago
T+20d
-56.04%
call +56.04% · α +54.25%
$0.4000
settled 3mo ago
T+60d
-55.53%
call +55.53% · α +56.71%
$0.4047
settled 6w ago

Price Chart

Loading chart...

Executive Summary

Soligenix filed an 8-K to increase the maximum aggregate offering amount under its existing at-the-market (ATM) equity facility with Rodman & Renshaw by $2,956,000, bringing the total to $6,406,000. The company had previously sold approximately $3,445,000 under the facility. This represents ongoing equity dilution for a micro-cap biotech with a $13M market cap.

Key Facts

  • ATM facility increased by $2,956,000 to a total maximum of $6,406,000
  • Prior sales under the facility totaled approximately $3,445,000
  • Shares sold through Rodman & Renshaw under the existing Sales Agreement dated January 23, 2026
  • Company market cap is approximately $13M, making the incremental offering ~23% of market cap

Financial Impact

Potential additional dilution of up to $2.96M in gross proceeds, representing ~23% of current $13M market cap

dilution

Risk Factors

  • Further dilution from continued ATM sales
  • Potential inability to raise sufficient capital if stock price declines
  • No disclosed revenue or near-term catalyst to offset dilution

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (7 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-067649
Document: sngx-20260528xex23d1.htm0001104659-26-067649
Document: sngx-20260528xex5d1.htm0001104659-26-067649
Document: 0001104659-26-067649-index-headers.html0001104659-26-067649
Document: 0001104659-26-067649-index.html0001104659-26-067649
Document: 0001104659-26-067649.txt0001104659-26-067649
5 reports for SNGX
Performance horizon
100% Hit rate 4 of 4 directional calls best @ T+20▲ +69.30%Apr 3, 2026
Filters
Rows
Reports for SNGX — sortable, filterable
TypeNow
Jun 26, 2026
13w ago
8-K
BEARISH ★ 6/10
$0.4000 $0.3850▲ +3.75%▲ +8.14%$0.3659 (+8.52%)
Jun 26, 2026
13w ago
424B5
BEARISH ★ 7/10
$0.4000 $0.3850▲ +3.75%▲ +8.14%$0.3659 (+8.52%)
May 28, 2026
18w ago
8-K
BEARISH ★ 5/10
$0.9100 $0.4047▲ +55.53%▲ +56.71%$0.3659 (+59.79%)
May 28, 2026
18w ago
424B5
BEARISH ★ 6/10
$0.9100 $0.4047▲ +55.53%▲ +56.71%$0.3659 (+59.79%)
Apr 3, 2026
26w ago
EFFECT
BEARISH ★ 6/10
$1.14 $0.3970▲ +65.18%▲ +78.64%$0.3659 (+67.90%)
Showing 5 of 5

US Market Status

Market Open — Closes in 3h 36m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access